<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271659</url>
  </required_header>
  <id_info>
    <org_study_id>2011-704</org_study_id>
    <nct_id>NCT02271659</nct_id>
  </id_info>
  <brief_title>Medical and Economic Evaluation for Intermediate-risk Prostate Cancer</brief_title>
  <acronym>GETUGP05</acronym>
  <official_title>Medical and Economic Evaluation of an External Beam Radiotherapy Combined With a Brachytherapy Boost Compared With an Exclusive External Beam Radiotherapy for Intermediate-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present phase III study is two-folded: 1) to show a superiority of external
      beam radiotherapy combined with a brachytherapy boost versus exclusive external beam
      radiotherapy and 2) to evaluate the economic impact of each treatment.

      The study includes 33 cancer centres, the inclusion time is of 2 years and the follow-up is
      of 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the biochemical relapse free survival of the patients in two groups at 5 years for an external beam radiotherapy with a brachytherapy boost versus an exclusive external beam radiotherapy</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical relapse is defined using the Phoenix definition of nadir of Prostate Specific Antigen + 2 ng/ml. This will be studied for both arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the overall survival at 5 years.</measure>
    <time_frame>5 years</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the specific survival at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Mortality due to prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the survival without any metastatic evolution at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The study of all toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>The toxicities include: acute and late toxicities, sexual toxicities, the quality of life of the patients (CTCAE version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical and economical evaluation.</measure>
    <time_frame>5 years</time_frame>
    <description>The complete medical and economical evaluation of the strategies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Brachytherapy boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exclusive external beam irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy boost with external beam radiotherapy</intervention_name>
    <description>Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.</description>
    <arm_group_label>Brachytherapy boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Exclusive external beam radiotherapy</intervention_name>
    <description>Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.</description>
    <arm_group_label>Exclusive external beam irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 80 years;

          -  life expectancy of greater than 10 years;

          -  prostate adenocarcinoma histologically proven;

          -  prostate cancer has to be of intermediate-risk based on at least one of the three
             following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7
             and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status
             ECOG 0-2.

          -  the patient has to be the beneficiary of the social security system (order n° 2006-477
             from April 26th 2006);

          -  the signed consent form.

        Exclusion Criteria:

          -  PSA level &gt; 20;

          -  Gleason &gt; 7;

          -  clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A
             won't be an exclusion criterion);

          -  prostate volume &gt; 60 cc;

          -  pelvic lymph nodes involvement at dissection or imaging (ADP &gt; 1.5 cm);

          -  concurrent hormone therapy;

          -  the presence of distant metastasis (M1);

          -  history of abdominal or pelvic irradiation;

          -  history of prostate resection in the previous 6 months and/or not allowing the
             implantation of markers;

          -  history of uncontrolled cancer and/or treated since less than 5 years (excepting the
             basal-cell carcinoma);

          -  urinary discomfort with an IPSS (International Prostate Symptom Score) &gt; 15 (without
             alpha-blocking);

          -  inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;

          -  other undergoing study that may interfere with the present study;

          -  patient under legal protection measure.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHAPET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier CHAPET, MD</last_name>
    <phone>0033 4 78 86 42 59</phone>
    <email>olivier.chapet@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BERTHILLER</last_name>
    <phone>0033 4 27 85 63 01</phone>
    <email>julien.berthiller@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent VOTRON, MD</last_name>
      <phone>5 63 77 77 50</phone>
      <phone_ext>0033</phone_ext>
      <email>votron@claude-bernard-albi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Jean MINJOZ</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasser HAMMOUD, MD</last_name>
      <phone>3 84 46 14 09</phone>
      <phone_ext>0033</phone_ext>
      <email>yhammoud@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie BONICHON-LAMICHHANE, MD</last_name>
      <phone>5 56 39 47 28</phone>
      <phone_ext>0033</phone_ext>
      <email>Bonichon-lamichhane@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence THOMAS, MD</last_name>
      <phone>5 56 33 33 20</phone>
      <phone_ext>0033</phone_ext>
      <email>Thomas@bergonie.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre MALHAIRE, MD</last_name>
      <phone>2 98 22 37 40</phone>
      <phone_ext>0033</phone_ext>
      <email>jean-pierre.malhaire@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marlon SILVA, MD</last_name>
      <phone>2 31 45 50 17</phone>
      <phone_ext>0033</phone_ext>
      <email>m.silva@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CREHANGE, MD</last_name>
      <phone>3 80 73 75 18</phone>
      <phone_ext>0033</phone_ext>
      <email>gcrehange@dijon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel BOLLA, MD</last_name>
      <phone>4 76 76 55 06</phone>
      <phone_ext>0033</phone_ext>
      <email>mbolla@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre Le Cancer Rhone-Alpes Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal POMMIER, MD</last_name>
      <phone>4 78 78 26 52</phone>
      <phone_ext>0033</phone_ext>
      <email>pommier@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie Mâcon</name>
      <address>
        <city>Macon</city>
        <zip>71031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice LORCHEL, MD</last_name>
      <phone>3 85 23 21 00</phone>
      <phone_ext>0033</phone_ext>
      <email>lorchel.fabrice@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naji SALEM, MD</last_name>
      <email>SALEMN@marseille.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen LLACER MOSCARDO, MD</last_name>
      <phone>4 67 61 31 34</phone>
      <phone_ext>0033</phone_ext>
      <email>carmen.llacer@valdorel.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier PEIFFERT, MD</last_name>
      <email>d.peiffert@nancy.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent CHAUVEINC, MD</last_name>
      <email>Laurent.chauveinc@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel HANNOUN LEVI, MD</last_name>
      <phone>4 92 03 12 60</phone>
      <phone_ext>0033</phone_ext>
      <email>Jean-Michel.HANNOUN-LEVI@nice.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain LABIB, MD</last_name>
      <email>alain.labib@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN, MD</last_name>
      <phone>1 42 49 90 24</phone>
      <phone_ext>0033</phone_ext>
      <email>christophe.hennequin@sls.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital George Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin HOUSSET, MD</last_name>
      <phone>1 56 09 34 21</phone>
      <phone_ext>0033</phone_ext>
      <email>martin.housset@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHAPET, MD</last_name>
      <phone>0033 4 78 86 42 59</phone>
      <email>olivier.chapet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane GUERIF, MD</last_name>
      <phone>5 49 44 44 85</phone>
      <phone_ext>0033</phone_ext>
      <email>s.guerif@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot,</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tan Dat NGUYEN, MD</last_name>
      <phone>3 26 50 43 51</phone>
      <phone_ext>0033</phone_ext>
      <email>tandat.nguyen@reims.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51057</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MALLET, MD</last_name>
      <phone>3 26 84 02 84</phone>
      <phone_ext>0033</phone_ext>
      <email>fmallet@iccreims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>50420</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud DE CREVOISIER, MD</last_name>
      <phone>2 99 25 30 31</phone>
      <phone_ext>0033</phone_ext>
      <email>Renaud.de.crevoisier@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henry Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed BENYOUCEF, MD</last_name>
      <phone>2 32 08 22 62</phone>
      <phone_ext>0033</phone_ext>
      <email>ahmed.Benyoucef@rouen.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Cancérologique de la Loire</name>
      <address>
        <city>Saint-priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy DE LAROCHE, MD</last_name>
      <phone>4 77 91 71 02</phone>
      <phone_ext>0033</phone_ext>
      <email>guy.delaroche@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius POP, MD</last_name>
      <phone>3 88 25 85 16</phone>
      <phone_ext>0033</phone_ext>
      <email>mpop@strasbourg.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BACHAUD Jean-Marc, MD</last_name>
      <email>bachaud.jean-marc@claudiusregaud.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto BOSSI, MD</last_name>
      <email>Alberto.BOSSI@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du TONKIN</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69626</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ARDIET Jean-Michel, MD</last_name>
      <phone>4 26 68 67 67</phone>
      <phone_ext>0033</phone_ext>
      <email>jean-michel.ardiet@wanadoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>external beam radiotherapy</keyword>
  <keyword>brachytherapy boost</keyword>
  <keyword>economical evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

